Uncategorized
Blocking AhR Sensor Activates Regenerative Program in Injured Neurons
A molecular switch in neurons regulates the regrowth of damaged axonal fibers. This is according to findings in mice, published in a new Nature paper titled “AhR inhibition promotes axon regeneration via a stress–growth switch, that show that blocking a protein called the aryl hydrocarbon receptor (AhR) may help neural regeneration and restore function after injuries to the peripheral nerves or spinal cords. The work is led by a team of scientists from the Icahn School of Medicine at Mount Sinai and their collaborators at other institutions.
It is an important piece to the puzzle of why neurons in adult mammals have a limited ability to regrow damaged axonal connections. Because of this limitation, injuries to the nerves or spinal cord often result in permanent loss of movement or sensation. “When neurons are injured, they must deal with stress while also trying to regrow their axons,” explained Hongyan Zou, MD, PhD, a professor of neurosurgery, and neuroscience, at the Icahn School of Medicine at Mount Sinai and the study’s senior author. AhR, which was originally identified as a xenobiotic sensor that detects environmental toxins and pollutants, appears to integrate environmental sensing and regenerative capabilities to regrow axons after injury.
As the scientists explain in Nature, “our work establishes AhR as a brake on axon regeneration that integrates transcriptional, metabolic and epigenetic programs to enforce proteostasis at the expense of regenerative growth.” Basically it “functions like a brake that shifts neurons toward managing stress rather than rebuilding damaged connections,” Zou said.
According to results reported in the paper, the team found that when AhR signaling is active, axon growth slows. But when the protein is removed from neurons or has its signaling activity blocked with drugs, axonal fibers grew more effectively. In fact, in mouse models of peripheral nerve injury and spinal cord injury, inhibiting AhR also improved recovery of motor and sensory function, the scientists wrote.
More detailed experiments helped elucidate how the process works. Following injury or stress, AhR helps neurons cope by maintaining proteostasis and reducing the protein production needed for growth. When it is turned off, neurons adopt a new protection strategy. They begin producing more protein and activate growth-related pathways that support axon regeneration. The growth process is also supported by HIF-1α, which helps regulate genes involved in metabolism and tissue repair.
These results point to some possible treatment directions for spinal cord injury, stroke, or other neurological diseases. Several drugs that block AhR are already being tested in clinical trials for other diseases, and they could eventually be studied in this context as well. However, more research is needed before this approach can be trialed in patients, the scientists said.
Future studies will examine how effective AhR inhibitors are in different types of neural damage, determine the best timing and dosage for treatment, and assess the impact of these treatments on other cells after injury. As part of their next steps, the Mount Sinai team plans to test AhR-blocking drugs and gene-therapy strategies designed to reduce the protein’s activity in neurons.
The post Blocking AhR Sensor Activates Regenerative Program in Injured Neurons appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Nature Biotechnology6 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Uncategorized5 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized4 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
STAT News – Biotech6 months agoSTAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
-
Nature Biotechnology6 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read